Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + HMA in Newly Diagnosed AML Ineligible for Intensive Chemotherapy
NCT07773909Phase 4Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
A Phase 4 trial of venetoclax, azacitidine, decitabine in acute myeloid leukemia (AML), sponsored by Bangabandhu Sheikh Mujib Medical University. Started Jun 2022; status: completed.
02
Drugs
venetoclaxazacitidinedecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07773909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07773909.